Chevy Chase Trust Holdings LLC Has $3.75 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Chevy Chase Trust Holdings LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,219 shares of the company’s stock after selling 299 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Medpace were worth $3,745,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MEDP. RiverPark Advisors LLC acquired a new position in Medpace during the 4th quarter valued at about $26,000. Contravisory Investment Management Inc. purchased a new position in shares of Medpace during the fourth quarter valued at approximately $26,000. Altshuler Shaham Ltd bought a new stake in Medpace during the fourth quarter worth $27,000. FinTrust Capital Advisors LLC purchased a new stake in Medpace in the 3rd quarter valued at $30,000. Finally, Rockefeller Capital Management L.P. lifted its stake in Medpace by 361.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock valued at $30,000 after acquiring an additional 112 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 1.0 %

Shares of MEDP stock opened at $404.77 on Wednesday. The firm has a market cap of $12.54 billion, a P/E ratio of 45.58, a PEG ratio of 2.12 and a beta of 1.38. The company has a 50 day moving average of $382.54 and a 200-day moving average of $312.99. Medpace Holdings, Inc. has a 12-month low of $185.43 and a 12-month high of $419.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.22 by $0.24. The business had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same period last year, the business posted $2.12 earnings per share. As a group, equities analysts expect that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now directly owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,340 shares of company stock valued at $76,651,647. 25.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Robert W. Baird boosted their price target on shares of Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $382.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.